429 related articles for article (PubMed ID: 27755997)
1. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
de Charette M; Marabelle A; Houot R
Eur J Cancer; 2016 Nov; 68():134-147. PubMed ID: 27755997
[TBL] [Abstract][Full Text] [Related]
2. Tumor immunotherapy: the tumor cell as an antigen-presenting cell.
Ostrand-Rosenberg S
Curr Opin Immunol; 1994 Oct; 6(5):722-7. PubMed ID: 7826527
[TBL] [Abstract][Full Text] [Related]
3. Selective MHC expression in tumours modulates adaptive and innate antitumour responses.
Rees RC; Mian S
Cancer Immunol Immunother; 1999 Oct; 48(7):374-81. PubMed ID: 10501850
[TBL] [Abstract][Full Text] [Related]
4. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
5. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
Bossi G; Buisson S; Oates J; Jakobsen BK; Hassan NJ
Cancer Immunol Immunother; 2014 May; 63(5):437-48. PubMed ID: 24531387
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of immune escape of cancer and its regulation.
Morita R; Hirohashi Y; Torigoe T
Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397
[No Abstract] [Full Text] [Related]
7. Playing hide and seek: Tumor cells in control of MHC class I antigen presentation.
Jongsma MLM; Neefjes J; Spaapen RM
Mol Immunol; 2021 Aug; 136():36-44. PubMed ID: 34082257
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of immune escape in the cancer immune cycle.
Tang S; Ning Q; Yang L; Mo Z; Tang S
Int Immunopharmacol; 2020 Sep; 86():106700. PubMed ID: 32590316
[TBL] [Abstract][Full Text] [Related]
9. Tumor escape from immune response: mechanisms and targets of activity.
Gabrilovich D; Pisarev V
Curr Drug Targets; 2003 Oct; 4(7):525-36. PubMed ID: 14535653
[TBL] [Abstract][Full Text] [Related]
10. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
[TBL] [Abstract][Full Text] [Related]
11. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach.
Joshi B; Wang X; Banerjee S; Tian H; Matzavinos A; Chaplain MA
J Theor Biol; 2009 Aug; 259(4):820-7. PubMed ID: 19446568
[TBL] [Abstract][Full Text] [Related]
12. Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F; Aptsiauri N
Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
[TBL] [Abstract][Full Text] [Related]
13. [Immunobiology of dendritic cells and their application in clinical practice].
Galamb O; Molnár B; Tulassay Z
Orv Hetil; 2003 Sep; 144(38):1873-9. PubMed ID: 14596026
[TBL] [Abstract][Full Text] [Related]
14. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
15. HLA class I expression on human cancer cells. Implications for effective immunotherapy.
Tait BD
Hum Immunol; 2000 Feb; 61(2):158-65. PubMed ID: 10717809
[TBL] [Abstract][Full Text] [Related]
16. Tumour MHC class I downregulation and immunotherapy (Review).
Bubeník J
Oncol Rep; 2003; 10(6):2005-8. PubMed ID: 14534734
[TBL] [Abstract][Full Text] [Related]
17. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
Svensson M; Pfeifer J; Stockinger B; Wick MJ
Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
[TBL] [Abstract][Full Text] [Related]
18. Tumor immunotherapy: cytokines and antigen presentation.
Lord EM; Frelinger JG
Cancer Immunol Immunother; 1998 Apr; 46(2):75-81. PubMed ID: 9558002
[TBL] [Abstract][Full Text] [Related]
19. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-tumor cell hybrids and immunotherapy: what's next?
Cathelin D; Nicolas A; Bouchot A; Fraszczak J; Labbé J; Bonnotte B
Cytotherapy; 2011 Aug; 13(7):774-85. PubMed ID: 21299362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
